{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 17 October 2006\line \line {\b Roche\u8217?s 
nine-month sales hit record high\line \line } Release 
as PDF: \u160?English (http://www.roche.com/mr3q06e.pdf) 
\u160?\u160?\u160?\u160?\u160?German (http://www.roche.com/mr3q06d.pdf) \u160?\u160?\u160?\u160?\u160?French (http://www.roche.com/mr3q06f.pdf) 
\u160?\u160?\u160?\u160?\u160?Spanish (http://www.roche.com/mr3q06sp.pdf)\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Presentation 
as PDF: English only (http://www.roche.com/irp3q06e.pdf)\line \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Group} \line \u8226? 
Group sets new records for nine-month sales and growth, as sales for the period rise 17%* to 30.3 billion 
Swiss francs\line \u8226? Sales continue to accelerate in both divisions, surpassing the strong 
growth recorded during the first half of 2006\line \line {\b Pharmaceuticals} \line \u8226? 
Pharmaceutical sales reach 23.9 billion Swiss francs, an increase of 21%, or almost four times the global 
market growth rate\line \u8226? Market share rise from 4.4% to 4.7% \u8212? Roche moves into sixth place 
among the world\u8217?s biggest drug makers (up from eighth place in 2005)\line \u8226? Cancer medicines 
deliver strong, 41% growth, reinforcing Roche\u8217?s leadership in oncology\line \u8226? Sixteen approvals 
in major markets, including worldwide marketing approvals for MabThera/Rituxan in rheumatoid arthritis, 
for Herceptin in early breast cancer (EU) and for Avastin in non-small cell lung cancer (US)\line \u8226? 
Fifteen regulatory filings in major markets, including Mircera for the treatment of renal anemia and 
Avastin for the treatment of lung and breast cancer\line \line {\b Diagnostics} \line \u8226? 
Roche Diagnostics posts 5% rise in sales; growth accelerates in third quarter\line \u8226? All business 
areas help grow sales ahead of the global market in third quarter\line \u8226? Shipment of insulin 
pumps to US resumed following removal of import alert\line \line {\b Outlook 
for 2006 reaffirmed} \line \u8226? Double-digit sales increases for the Roche Group and the 
Pharmaceuticals Division; above-market growth in Diagnostics\line \u8226? Target is for Core Earnings 
per Share to grow ahead of sales\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 * Unless otherwise 
stated, all growth 
rates are based on local currencies.\par}\line \line \line Commenting 
on the 
Group\u8217?s performance in the first nine months of 2006, Roche Chairman and CEO Franz B. Humer said, \u8216?In 
the third quarter Roche continued to grow well ahead of the market. Our oncology medicines and Tamiflu 
remain the major growth drivers in the Pharmaceuticals Division. In Diagnostics, Diabetes Care is back 
on growth track, with all other divisional business areas also contributing to increased sales. We are 
very confident about achieving our ambitious goals for the full year \u8211? both in terms of sales and profits 
and in terms of advancing our development programmes.\u8217?\line \line \line \line {\b Roche 
Group} \line \line 
		 20062005% Change% Change
	
		Sales from January to September1m CHFmCHFIn CHFIn local currencies
	
		Pharmaceuticals Division23,91219,434+23+21
	
		        Roche 14,92112,169+23+20
	
		        Genentech 6,5224,632+41+37
	
		        Chugai 2,4692,633-6-2
	
		Diagnostics Division6,4156,008+7+5
	
		Roche Group30,32725,442+19+17
	\line {\pard\f0\li0\ri0\sa360\sl360\fs18 1 
See attachment to this release for details on quarterly sales growth.\par}\par}Roche posted 
sales of 30.3 billion Swiss francs in the first nine months of 2006, an increase of 17% in local currencies 
(19% in Swiss francs; 16% in US dollars) over the same period last year. The Group thus surpassed the 
high growth rates reported for the first half-year. Nine-month sales in the Pharmaceuticals Division 
increased 21% (23% in Swiss francs), or almost four times as fast as the global market. The Diagnostics 
Division\u8217?s sales rose 5% (7% in Swiss francs), and in the third quarter the division extended its market 
lead.\line \line {\b Outlook} \line Barring unforeseen events, 
Roche expects full-year sales and income for 2006 to be up significantly from 2005. As announced at 
the presentation of the 2006 interim results, sales in both the Pharmaceuticals and the Diagnostics 
Division are expected to grow ahead of the market in local currencies. Roche anticipates double-digit 
sales growth for the Pharmaceuticals Division and the Group as a whole. Roche\u8217?s target is for Core Earnings 
per Share (EPS) to grow ahead of sales.\line \line \line \line {\b Pharmaceuticals 
Division} \line \line Sales growth in the Pharmaceuticals 
Division accelerated further during the first nine months of 2006, increasing to 21% in local currencies 
(23% in Swiss francs; 20% in US dollars), or almost four times the global market rate (6%). Roche\u8217?s 
market share rose from 4.4% to 4.7%, putting the Group in sixth place among the world\u8217?s biggest drug 
makers \u8211? up from eighth place last year. Regional sales growth significantly outpaced the market average 
in North America (27% vs 7%) and Europe (23% vs 5%). In Japan sales declined slightly (\u8211?2% vs \u8211?1%) due 
to government-mandated price cuts. Continued strong demand for the division\u8217?s oncology products, ongoing 
pandemic stockpiling of the influenza medicine Tamiflu and sales of the osteoporosis medicine Bonviva/Boniva 
were the main factors driving robust growth during the period.\line \line {\b Oncology 
\u8212? strong sales growth continues} \line With sales up 41%, the division\u8217?s oncology products 
continued to deliver outstanding growth, reinforcing Roche\u8217?s position as the world\u8217?s leading provider 
of cancer medicines.\line \line Sales of MabThera/Rituxan, for non-Hodgkin\u8217?s lymphoma 
(NHL), continued to grow strongly, advancing 15%. Growth is currently being driven by first-line use 
in indolent and aggressive NHL. In July Roche received EU regulatory approval to market MabThera for 
maintenance therapy in patients with relapsed or refractory follicular NHL giving these patients a better 
chance to live disease-free for longer.\line \line Sales of Herceptin, for HER2-positive 
breast cancer, almost doubled compared with the first nine months of 2005. Data showing an impressive 
survival benefit with Herceptin in early-stage breast cancer have been very well received by physicians 
and have led to several fast-tracked regulatory and reimbursement approvals in the EU and other key 
markets. Recently announced positive data from the phase III TAnDEM trial, investigating Herceptin in 
combination with hormone therapy for metastatic breast cancer, have been filed with European regulatory 
authorities in October.\line \line Avastin, a cancer therapy with demonstrated survival 
benefits in metastatic colorectal, breast and lung cancer, posted a 90% increase in sales. Moreover, 
use of the medicine is expected to increase further now that reimbursement is widely in place in Europe 
for the treatment of metastatic colorectal cancer (MCRC). To further expand the MCRC label for both 
Avastin and Xeloda, two additional applications \u8212? based on data from the largest ever conducted first-line 
MCRC study and supportive trial data from other studies \u8212? will be submitted simultaneously in the first 
half of 2007. Following priority review, the world\u8217?s first angiogenesis inhibitor was approved by the 
FDA in October for the treatment of non-small cell lung cancer (NSCLC); a filing for the same indication 
was submitted to EU authorities in August. In addition, Avastin was filed with US and EU regulators 
for the treatment of advanced breast cancer in May and July, respectively. In September the FDA requested 
additional data analysis to support the filing in advanced breast cancer, though there are no concerns 
about the drug\u8217?s efficacy or safety. Genentech will supply the requested data by mid-2007.\line \line Xeloda 
continues to post strong sales growth (22%), performing well in both the US and the EU. A filing for 
approval of the drug to treat stomach cancer was submitted to EU regulators in July. Positive data from 
a phase III trial have demonstrated the equivalent efficacy of an oral Xeloda-containing regimen compared 
with an intravenous 5FU-containing regimen in first-line MCRC. Data from a phase III study in second-line 
MCRC (comparing Xeloda/oxaliplatin vs 5FU/oxaliplatin) are expected in early 2007. The combined results 
of these studies will be used for global filings in the first half of 2007.\line \line Tarceva, 
a novel, targeted drug that has been shown to extend the lives of patients with advanced NSCLC and pancreatic 
cancer patients, remained on growth track in both the US and the EU with a sharp, 130% rise in sales. 
A pivotal phase III trial (RADIANT) is under way to support expanded labelling for use in NSCLC in the 
adjuvant setting. In September Roche requested a re-examination of the data supporting its filing for 
Tarceva for the treatment of pancreatic cancer, after the EU\u8217?s Committee for Medicinal Products for 
Human Use (CHMP) issued a negative opinion despite a statistically significant survival benefit with 
the drug in this indication.\line \line {\b Anaemia \u8212? sales steady in 
a highly competitive market} \line Combined sales of Roche\u8217?s NeoRecormon and Chugai\u8217?s 
Epogin were stable overall. NeoRecormon grew 6% and retained its leadership position in its markets, 
despite sustained pressure on pricing in the renal anemia and oncology segments. In Japan, where Epogin 
remains the market leader for renal anemia, sales declined 12% due to government-mandated price cuts 
and reimbursement changes, which resulted in a contraction of the overall anemia market. Roche filed 
Mircera, the first continuous erythropoietin receptor activators (CERAs), with the US and European regulatory 
authorities in April for the treatment of anemia associated with chronic kidney disease.\line \line {\b Transplantation} \line Sales 
of CellCept, the world\u8217?s top-selling branded immunosuppressant for the prevention of organ transplant 
rejection, rose 7% for the period, despite emerging generic competition in some Latin American markets.\line \line {\b Virology 
\u8212? Tamiflu stockpiling sales continue to grow } \line Worldwide, sales of Tamiflu rose 
to 1.6 billion Swiss francs, an increase of 88% over the same period last year. Growth was driven mainly 
by pandemic stockpiling sales as some governments increased their population coverage. A Tamiflu supply 
chain capable of producing 80 million treatments a year is now fully operational in the US. This addition 
to the Roche network will bring total annual production capacity to 400 million treatment courses by 
the end of 2006, ensuring that enough Tamiflu is available both for pandemic preparedness and for use 
against seasonal influenza. Sales of Pegasys rose 2%, while Copegus sales continued to decline due to 
generic erosion in the US.\line Sales of the anti-HIV medicine Fuzeon advanced 22%.\line \line {\b Primary 
care \u8212? Bonviva/Boniva gains market share} \line Sales of once-monthly oral Bonviva/Boniva 
continued to increase, reaching 309 million Swiss francs in a highly competitive market. Boniva now 
accounts for about 15% of new prescriptions in the US, and launches are ongoing across Europe and the 
rest of the world. Data presented for the first time in September, at the Annual Meeting of the American 
Society of Bone Mineral Research, show that patients on monthly Boniva tend to stay on their treatment 
significantly longer than those taking weekly bisphosphonates. This raises the prospect of better treatment 
outcomes.\line Xenical, for weight loss, continued to post steady growth (7%).\line \line {\b Rheumatoid 
arthritis \u8212? MabThera/Rituxan approved for autoimmune indication} \line Following US approval 
in February, MabThera has also been approved in the EU for use in rheumatoid arthritis (RA) patients 
with an inadequate response to \u8220?anti TNF\u8221? biologic therapies. MabThera/Rituxan is the first medicine 
shown to be effective in preventing joint damage in this patient population.\line \line {\b Development 
\u8212? important milestones achieved} \line In addition to receiving 16 approvals and filing 
for 15 more indications in major markets, Roche again achieved a significant number of milestones in 
developing new drugs and indications.\line \line An international phase III study 
(NO16966) involving 2,035 previously untreated metastatic colorectal cancer patients met both primary 
endpoints. Results of the study showed that the chemotherapy combination Xeloda plus oxaliplatin (XELOX) 
was as effective in terms of progression-free survival as infused 5-FU/leucovorin plus oxaliplatin (FOLFOX). 
Secondly, the addition of Avastin to chemotherapy (FOLFOX and XELOX) significantly improved progression-free 
survival compared with chemotherapy alone.\line \line Data presented at this year\u8217?s 
Congress of the European Society for Medical Oncology show that adding Herceptin to hormone therapy 
significantly prolongs progression-free survival in patients with advanced hormone receptor-positive, 
HER2-positive breast cancer, compared with hormone therapy alone.\line \line The 
results of three phase III maintenance therapy trials presented at the Congress of the European Renal 
Association - European Dialysis and Transplant Association show that dialysis patients treated with 
short-acting and frequently administered anti-anemia drugs can be switched directly to once-monthly 
Mircera and maintain stable hemoglobin levels.\line \line Genentech and its partner 
Biogen Idec have announced that a phase II proof of concept study of MabThera/Rituxan for relapsing-remitting 
multiple sclerosis has met its primary endpoint.\line \line Roche has exercised 
its option to license Ipsen\u8217?s glucagon-like peptide-1 (GLP-1) analogue for type 2 diabetes. A phase 
II study to confirm the efficacy and safety of this compound in a sustained release formulation is scheduled 
to start early in 2007.\line \line Roche entered into several major new alliances 
during the third quarter. In July Roche and Actelion signed an exclusive worldwide agreement to collaborate 
on developing and commercialising Actelion\u8217?s selective S1P1 receptor agonist for multiple autoimmune 
diseases. In October Roche and Plexxikon agreed to collaborate on a novel oral drug for several different 
cancers, and an alliance with InterMune, also announced in October, has strengthened Roche\u8217?s research 
activities targeting hepatitis C.\line \line R873 in male erectile dysfunction has 
been discontinued, as it did not meet Roche\u8217?s hurdles for medical differentiation. After clarification 
of the regulatory framework for the class of integrin antagonists, R411 was discontinued in the development 
of asthma. However, clinical development was started in multiple sclerosis. R1438 (DPPIV inhibitor) 
in diabetes did not show enough clinical differentiation and, therefore, had been replaced by a back-up 
compound which indicated the profile as requested.\line \line \line \line {\b Diagnostics 
Division} \line \line Roche Diagnostics\u8217? sales rose 5% in 
local currencies (7% in Swiss francs; 4% in US dollars) in the first nine months of 2006. Following 
gains of 3% and 5% in the first and second quarters, divisional sales accelerated to a third-quarter 
increase of 6%. All five business areas contributed to growth, with Roche Applied Science and Roche 
Near Patient Testing posting double-digit increases in sales.\line \line Sales in 
Iberia/Latin America and Eastern Europe advanced at double-digit rates, while growth in the Asia-Pacific 
and Europe-Middle East-Africa (EMEA) regions was in the single-digits. Divisional sales in Japan continued 
to outpace the market, and growth was also positive in the US. In October the FDA lifted its import 
alert barring US importation of Accu-Chek insulin pumps from Disetronic Medical Systems AG (Burgdorf, 
Switzerland). Pump shipments to the US market have already resumed.\line \line {\b Diabetes 
Care \u8212? Accu-Chek Spirit launched in US} \line Fuelled by a third-quarter increase of 5%, 
Roche Diabetes Care\u8217?s sales accelerated to a growth rate of 2% for the first nine months of the year. 
Accu-Chek Aviva generated high sales volumes in the major EMEA markets and in the US and Canada, as 
did Accu-Chek Active in Latin America and the Asia-Pacific region. The removal of the FDA\u8217?s import alert 
will enable swift progress on providing worldwide access to Roche\u8217?s full insulin delivery portfolio. 
Today, Accu-Chek Spirit is available in more than 30 countries. Outside the US, the Group\u8217?s insulin 
delivery business posted 15% growth.\line \line {\b Centralized Diagnostics 
\u8212? successful rollout of new cobas 6000 analyser series} \line Roche Centralized Diagnostics 
recorded a 5% rise in overall sales, outpacing an average growth rate of 4% in this market segment. 
The first configurations of the cobas 6000 analyser series, launched in June 2006, have begun contributing 
to growth. Centralized Diagnostics\u8217? immunochemistry business achieved strong growth, with sales advancing 
by 13%, or nearly three times the market growth rate. The cardiac marker NT-proBNP showed a further 
increase in sales and is on its way to becoming one of the business area\u8217?s top-selling reagents.\line \line {\b Molecular 
Diagnostics \u8212? continued leadership} \line Roche Molecular Diagnostics increased its sales 
by 4%, thus maintaining its leading market share in an increasingly competitive business. Its largest 
segment, virology, grew 6%, helped by intensified marketing of the Cobas AmpliPrep/Cobas TaqMan systems 
in the Eastern European and Asian markets. In the blood screening segment, Roche continued to increase 
sales with ongoing roll out of its cobas s 201 system and multiplex HIV, HCV and HBV test in the EU. 
These products are now available in all European countries. \line \line {\b Near 
Patient Testing \u8212? new CoaguChek approval} \line Roche Near Patient Testing\u8217?s sales grew 
11%. FDA approval of the CoaguChek XS system in the US and the successful introduction of the system 
there and in many other countries strengthened Roche\u8217?s leadership in the coagulation monitoring market. 
Blood gas and electrolyte testing products, the product portfolio for blood glucose testing in hospitals 
and the rollout of the Cardiac proBNP assay all contributed to solid sales growth.\line \line {\b Applied 
Science \u8212? strong demand for LightCycler and Genome Sequencer} \line Roche Applied Science 
posted 12% sales growth. The LightCycler 480 instrument, the Genome Sequencer 20 system and products 
for industrial use were the main contributors to this double-digit increase. The Genome Sequencer 20 
system is being used in an increasing number of applications and contributed significantly to Applied 
Science\u8217?s nine-month performance. \line \line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of 
innovative products and services for the early detection, prevention, diagnosis and treatment of disease, 
the Group contributes on a broad range of fronts to improving people\u8217?s health and quality of life. Roche 
is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and 
a market leader in virology. In 2005 sales by the Pharmaceuticals Division totalled 27.3 billion Swiss 
francs, and the Diagnostics Division posted sales of 8.2 billion Swiss francs. Roche employs roughly 
70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, 
including majority ownership interests in Genentech and Chugai. Additional information about the Roche 
Group is available on the Internet (www.roche.com (http://www.roche.com)).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\line \line \line Annex (http://www.roche.com/mr3q06ane.pdf)\line \line \line {\b Additional 
information} \line - Roche Pharma pipeline\line - Date of 
publication of full-year results for 2006: 7 February 2007 (tentative)\line \line \line {\b {\i Disclaimer: 
Cautionary statement regarding forward-looking statements} } \line {\i This 
document contains certain forward-looking statements. These forward-looking statements may be identified 
by words such as \u8216?believes\u8217?, \u8216?expects\u8217?, \u8216?anticipates\u8217?, \u8216?projects\u8217?, \u8216?intends\u8217?, \u8216?should\u8217?, \u8216?seeks\u8217?, \u8216?estimates\u8217?, 
\u8216?future\u8217? or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. 
Various factors may cause actual results to differ materially in the future from those reflected in 
forward-looking statements contained in this document, among others: (1) pricing and product initiatives 
of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability 
in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange 
rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing 
of new products or new uses of existing products, including without limitation negative results of clinical 
trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased 
government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate 
protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; 
and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not 
a profit forecast and should not be interpreted to mean that Roche\u8217?s earnings or earnings per share 
for 2006 or any subsequent period will necessarily match or exceed the historical published earnings 
or earnings per share of Roche.} 
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}